Inflammatory Disease News and Research

RSS

Scientists identify key genes for Silk Road disease

Scientists have identified key genes responsible for a severe inflammatory disease that has spread along the old silk trading routes from the Far East to the edge of Europe.University of Manchester researchers, working as part of a large international consortium, have revealed some of the genetic mutations that lead to Behçet's disease. The group's findings are published in Nature Genetics.

21 Jul 2010

Amira achieves two clinical development milestones in FLAP program for asthma

"Amira Pharmaceuticals, Inc. announced today that its FLAP (5-lipoxygenase-activating protein) program, which is partnered with GlaxoSmithKline, has achieved two clinical development milestones."

19 Jul 2010

$235 million announced for expansion of biotech sector at CSL

A $235 million expansion of Australia's largest biotech facility in Melbourne is planned and this is expected to create hundreds of jobs. CSL biopharmaceutical research complex in Broadmeadows, in the north of Melbourne will be receiving this financial aid from both the State as well as Federal government over a five year investment plan. This will create an estimated 320 temporary construction jobs and later 333 new highly-skilled medical research openings by 2018.

15 Jul 2010

Starpharma gets FDA nod to start phase 2 bacterial vaginosis study for VivaGel

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced it had received clearance from the US Food and Drug Administration (FDA) to commence a phase 2 study to investigate VivaGel® for the treatment of bacterial vaginosis (BV).

15 Jul 2010

Individual genes and networks that play an important role in inflammation, atherosclerosis identified

HemoShear, LLC, a leading developer of innovative, cell-based, human surrogate models for discovery and assessment of new drug compounds, has produced a profile of all of the genes that influence the biology and function of the human artery system. This research has generated valuable information on the entire spectrum of genes that are found in specific cell-types that make up human arteries.

14 Jul 2010

Amira granted UK patents for AM103, AM803 FLAP inhibitors for respiratory disorders

Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted patent number GB2431927, titled, "5-Lipoxygenase Activating Protein (FLAP) Inhibitors," which includes coverage of Amira's AM103 and AM803 FLAP inhibitors for the treatment of respiratory disorders.

14 Jul 2010

Fear of having something in uterus deters teen girls from using intrauterine devices for birth control

Very few teenage girls in the United States use intrauterine devices for birth control, even though studies show they are safe, effective and extremely low-maintenance, according to researchers at Lucile Packard Children's Hospital and the Stanford School of Medicine.

9 Jul 2010

WSBI, University of Colorado sign licensing agreement for TCISM targets

Western States Biopharmaceuticals, Inc., a privately-held biotechnology company focusing on the development of novel therapies to treat inflammatory disease, and the University of Colorado announced today that they have entered into a licensing agreement for approaches to inhibiting newly discovered T cell Cytokine Inducing Surface Molecules, or TCISM autoimmune disease drug discovery targets.

8 Jul 2010

Initial Phase II study results of ofatumumab in patients with RRMS announced

Genmab A/S announced today positive interim results from an ofatumumab Phase II safety and pharmacokinetics study in patients with relapsing-remitting multiple sclerosis.

7 Jul 2010

UCLA study highlights traffic-related asthma flares in urban areas

A new academic study led by UCLA scientists has found that even brief exposure to ultrafine pollution particles near a Los Angeles freeway is potent enough to boost the allergic inflammation that exacerbates asthma.

2 Jul 2010

Bortezomib may offer hope for treating inflammatory diseases: New research

Those looking for a new treatment for a range of inflammatory diseases like arthritis, multiple sclerosis, inflammatory bowel disease, and lupus may need to look no further than a drug already available for treating cancer. In a research report published in the July 2010 print issue of the Journal of Leukocyte Biology, Japanese scientists use mice to show that bortezomib, currently used to treat cancers that affect white blood cells, induces cell death only in harmful (active and proliferating) T cells, leaving the rest unharmed.

1 Jul 2010

BIND Biosciences announces $12.4 million Series C-1 financing

BIND Biosciences, Inc. (BIND), a privately held biopharmaceutical company developing best in class therapeutics based on its proprietary targeted nanotechnology platform, announced today that it has secured a $12.4 Million Series C-1 financing. This financing included all of BIND's current investors (including Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension and DHK Investments) as well as a new venture investor, Endeavour Vision, and private investors.

29 Jun 2010

Endometriosis can affect women's work productivity

29 Jun 2010

FDA grants Abbott 510(k) clearance to market molecular diagnostic test for detection of chlamydia, gonorrhea

Abbott announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market a new, sensitive molecular diagnostic test and instrument to simultaneously detect two of the nation's most prevalent sexually transmitted diseases (STDs), gonorrhea and chlamydia, including a new variant strain of chlamydia recently discovered in Sweden.

28 Jun 2010

Eisai, Morphotek receive clearance for MORAb-022 Phase I clinical trial for rheumatoid arthritis

Eisai Inc. and Morphotek®, Inc. announced today that the Medical Ethical Review Committee and Central Committee on Research Involving Human Subjects of the Netherlands cleared its Clinical Trial Application to test the investigational new drug MORAb-022 in a Phase I clinical trial that will include both normal healthy volunteers and subjects diagnosed with rheumatoid arthritis.

28 Jun 2010

Study finds significant loss of work productivity among women who suffer from endometriosis

The first worldwide study of the societal impact of endometriosis has found a significant loss of work productivity among those women who suffer from the condition, a researcher told the 26th annual meeting of the European Society of Human Reproduction and Embryology today (Monday). Dr. Kelechi Nnoaham, from the Department of Public Health, University of Oxford, UK, said that the results of this multi-centre study would help highlight the previously unrecognised plight of an estimated 176 million women around the world whose lives are affected by endometriosis.

28 Jun 2010

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, will be presenting new preclinical data in an animal model of Type 2 diabetes in which its anti-inflammatory therapeutic antibody candidate, XOMA 052, was used as monotherapy and in combination with the marketed anti-diabetic drugs exendin-4 (Byetta) or sitagliptin (Januvia).

28 Jun 2010

Cardio-respiratory aerobic exercise reduces joint pain in RA patients

Researchers from the University of Grenoble Medical School in France determined that cardio-respiratory aerobic exercise is safe for patients with stable rheumatoid arthritis (RA).

25 Jun 2010

Johns Hopkins School of Medicine develops RAALI for healthcare providers

The Johns Hopkins School of Medicine, the nation's leading medical school recipient of research funds from the National Institutes of Health and a recognized center for "Best Practices" by the Accreditation Council for Continuing Medical Education, discussed the development of a unique medical education initiative - the Rheumatoid Arthritis Action Lab Initiative - to give healthcare providers connectivity to much-needed information on rheumatoid arthritis.

23 Jun 2010

Ensemble Discovery announces name change to Ensemble Therapeutics Corporation

Ensemble Discovery today announced that it will begin operating as Ensemble Therapeutics Corporation to reflect the Company's progress and emerging pipeline by applying its macrocycle drug platform to develop novel therapeutics. The new name, Ensemble Therapeutics, conveys the company's leadership and advancement in developing novel macrocycle drug compounds that are small molecules with expanded therapeutic properties of large molecule biological drugs.

22 Jun 2010